CLOUDBREAK-B Shareholder Deposits Shares with Construction Asia, Holdings Valued at HK$194 Million

Stock News03-19

Hong Kong stock exchange data reveals that on March 18, a shareholder of CLOUDBREAK-B deposited shares with Construction Asia. The deposited holdings are valued at HK$194 million, representing 11.23% of the company's shares. On February 16, CLOUDBREAK-B announced that its wholly-owned U.S. subsidiary, ADS Therapeutics LLC, had completed the review period for the Investigational New Drug application submitted to the U.S. Food and Drug Administration for CBT-199. CBT-199 is a potential best-in-class ophthalmic drug candidate developed by the group, with the application submitted on December 12, 2025. As the FDA did not issue any clinical hold order, the IND is now effective, and the clinical trial is deemed safe to proceed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195290026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 08:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195290026","market":"nz","top_or_hot":-1,"title":"CLOUDBREAK-B Shareholder Deposits Shares with Construction Asia, Holdings Valued at HK$194 Million","media":"Stock News","content":"<p>Hong Kong stock exchange data reveals that on March 18, a shareholder of CLOUDBREAK-B deposited shares with Construction Asia. The deposited holdings are valued at HK$194 million, representing 11.23% of the company's shares. On February 16, CLOUDBREAK-B announced that its wholly-owned U.S. subsidiary, ADS Therapeutics LLC, had completed the review period for the Investigational New Drug application submitted to the U.S. Food and Drug Administration for CBT-199. CBT-199 is a potential best-in-class ophthalmic drug candidate developed by the group, with the application submitted on December 12, 2025. As the FDA did not issue any clinical hold order, the IND is now effective, and the clinical trial is deemed safe to proceed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOUDBREAK-B Shareholder Deposits Shares with Construction Asia, Holdings Valued at HK$194 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOUDBREAK-B Shareholder Deposits Shares with Construction Asia, Holdings Valued at HK$194 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-19 08:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong stock exchange data reveals that on March 18, a shareholder of CLOUDBREAK-B deposited shares with Construction Asia. The deposited holdings are valued at HK$194 million, representing 11.23% of the company's shares. On February 16, CLOUDBREAK-B announced that its wholly-owned U.S. subsidiary, ADS Therapeutics LLC, had completed the review period for the Investigational New Drug application submitted to the U.S. Food and Drug Administration for CBT-199. CBT-199 is a potential best-in-class ophthalmic drug candidate developed by the group, with the application submitted on December 12, 2025. As the FDA did not issue any clinical hold order, the IND is now effective, and the clinical trial is deemed safe to proceed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1195290026","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195290026","pubTimestamp":1773880581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hong Kong stock exchange data reveals that on March 18, a shareholder of CLOUDBREAK-B deposited shares with Construction Asia. The deposited holdings are valued at HK$194 million, representing 11.23%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02592":"拨康视云-B"},"translate_title":"CLOUDBREAK-B股东向亚洲建设存股，持股价值1.94亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1},"content_text":"Hong Kong stock exchange data reveals that on March 18, a shareholder of CLOUDBREAK-B deposited shares with Construction Asia. The deposited holdings are valued at HK$194 million, representing 11.23% of the company's shares. On February 16, CLOUDBREAK-B announced that its wholly-owned U.S. subsidiary, ADS Therapeutics LLC, had completed the review period for the Investigational New Drug application submitted to the U.S. Food and Drug Administration for CBT-199. CBT-199 is a potential best-in-class ophthalmic drug candidate developed by the group, with the application submitted on December 12, 2025. As the FDA did not issue any clinical hold order, the IND is now effective, and the clinical trial is deemed safe to proceed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195290026","isCrawlerRequest":true}